Clinical trials “Efficacy of Favipiravir (T705) in reducing mortality in adults at early stage of Ebola Virus Disease in Guinea: a phase IIb trial
The primary objective of this workpackage is to assess the efficacy of high-dose Favipiravir in decreasing mortality in adults with EVD who start treatment early.
The secondary objectives are: to assess the efficacy of Favipiravir in decreasing plasma RNA and infectious loads; to assess the tolerance of the drug; and to describe the evolution of viral subpopulations of EBOV (including the analysis of mutations potentially associated with antiviral resistance) using deep sequencing approaches.
Prof. Denis Malvy (WP lead)
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (France):
Prof. France Mentré (co-lead), Prof. Hervé Raoul
UNIVERSITE D'AIX MARSEILLE (France):
Prof. Xavier De Lamballerie (WP co-lead)
INSTITUT PASTEUR (France):
Dr. Sylvain Baize